2-(MORFOLIN-4-IL)-1,7-NAFTIRIDINAS
Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son independientemente hidrogeno o metilo, adicionalmente se refiere a una compuesto Ib, donde: R1 es 1H-pirazol-3-il, R2 es hidrogeno, halogeno,...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | Spanish |
Published |
15.06.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son independientemente hidrogeno o metilo, adicionalmente se refiere a una compuesto Ib, donde: R1 es 1H-pirazol-3-il, R2 es hidrogeno, halogeno, entre otros; R4 es hidrogeno o metilo. Son compuestos preferidos: 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-N-etoxicarbonil-S-metilsulfoximida; 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-S-metilsulfoximida; entre otros. Tambien se refiere a una composicion y a una combinacion farmaceutica. Dichos compuestos derivados de 2-(morfolin-4-il)-1,7-naftiridina son utiles en el tratamiento de enfermedades hiperproliferativas
The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib),
to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. |
---|---|
AbstractList | Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son independientemente hidrogeno o metilo, adicionalmente se refiere a una compuesto Ib, donde: R1 es 1H-pirazol-3-il, R2 es hidrogeno, halogeno, entre otros; R4 es hidrogeno o metilo. Son compuestos preferidos: 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-N-etoxicarbonil-S-metilsulfoximida; 4-[(2-(morfolin-4-il)-8-[2H-pirazol-3-il]-[1,7]-naftiridin-4-il]fenil-S-metilsulfoximida; entre otros. Tambien se refiere a una composicion y a una combinacion farmaceutica. Dichos compuestos derivados de 2-(morfolin-4-il)-1,7-naftiridina son utiles en el tratamiento de enfermedades hiperproliferativas
The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib),
to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. |
Author | LUCKING, Ulrich BONE, Wilhelm BADER, Benjamin WORTMANN, Lars EIS, Knut WEDLER, Christine EBERSPACHER, Uwe SCHICK, Hans LEFRANC, Julien MOOSMAYER, Dieter WENGNER, Antje Margret BRIEM, Hans KOPPITZ, Marcus VON NUSSBAUM, Franz GRUDZINSKA-GOEBEL, Joanna LIENAU, Philip SIEMEISTER, Gerhard |
Author_xml | – fullname: KOPPITZ, Marcus – fullname: EBERSPACHER, Uwe – fullname: WORTMANN, Lars – fullname: SIEMEISTER, Gerhard – fullname: WEDLER, Christine – fullname: BADER, Benjamin – fullname: MOOSMAYER, Dieter – fullname: VON NUSSBAUM, Franz – fullname: LUCKING, Ulrich – fullname: WENGNER, Antje Margret – fullname: BONE, Wilhelm – fullname: LIENAU, Philip – fullname: SCHICK, Hans – fullname: LEFRANC, Julien – fullname: BRIEM, Hans – fullname: EIS, Knut – fullname: GRUDZINSKA-GOEBEL, Joanna |
BookMark | eNrjYmDJy89L5WRQMtLV8PUPcvP38fTTNdH19NHUNdQx1_VzdAvxDPJ08fRzDOZhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfEBrkYGhuYGZmZmjobGxKgBAMHnI2w |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
ExternalDocumentID | PE20170666A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_PE20170666A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 12:58:10 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | Spanish |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_PE20170666A13 |
Notes | Application Number: PE2017000168 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170615&DB=EPODOC&CC=PE&NR=20170666A1 |
ParticipantIDs | epo_espacenet_PE20170666A1 |
PublicationCentury | 2000 |
PublicationDate | 20170615 |
PublicationDateYYYYMMDD | 2017-06-15 |
PublicationDate_xml | – month: 06 year: 2017 text: 20170615 day: 15 |
PublicationDecade | 2010 |
PublicationYear | 2017 |
RelatedCompanies | BAYER PHARMA AKTIENGESELLSCHAFT |
RelatedCompanies_xml | – name: BAYER PHARMA AKTIENGESELLSCHAFT |
Score | 2.9540942 |
Snippet | Se refiere a un compuesto de formula I, donde: R1 es 1H-pirrol-2-il, 1H-pirrol-3-il o 1H-pirazol-3-il; R2 es hidrogeno, halogeno, CN, entre otros; R3 y R4 son... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | 2-(MORFOLIN-4-IL)-1,7-NAFTIRIDINAS |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170615&DB=EPODOC&locale=&CC=PE&NR=20170666A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ZS8QwEB6WVdQ3XRVdD1SkKBjskV4PRbo92Mr2oFbZt2UTW9AHXWzFv--kdF1f9C3JwOSAL18mmZkAXM4ZU22Ta4RrVCVUfzaJLasVQXKtKNKFwWURnBwnxviR3k_1aQ9el7EwbZ7QrzY5IiKKI96bdr9erC6x_Na3sr5lL9j0fhcWji911rHIBaPokj9ygiz1U0_yPCcLpCTvZIbhoqW0hsdoU6AheBqJqJTFb0oJt2E9Q21vzQ70ynoAm97y57UBbMTdgzcWO-zVu3Chkqs4zcN0EiWEkmhyTZQbkyRuWER55EeJ-7AH52FQeGOCnc1-ZjbLgtW4tH3oo8VfHsCZUso2t5kscrFRbltMq6y5pfOyqhCQJTuE4d96hv8Jj2BLVISvk6IfQ7_5-CxPkFUbdtouxzfU23ZK |
link.rule.ids | 230,309,783,888,25576,76876 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTkXnt0hRMNiPtF0fhmz9YNV-UevYW1liC_qgw1X8972UzvmibyEHl0vgl18uubsAXM4YUy2Ta4RrVCVUfzaJJaslQXItKdKFwWWRnBxGxviJ3k_1aQtel7kwdZ3Qr7o4IiKKI96rer-ery6xnDq2cnHLXrDr_c7LBo7UeMeiFoyiS85o4CaxE9uSbQ8SV4rSRmYYQ_SU1vCIbQo0uJORyEqZ_6YUbwvWE9T2Vm1Dq1h0oWMvf17rwkbYPHhjs8HeYgcuVHIVxqkXB35EKPGDa6LcmCQaepmf-o4fDR934dxzM3tMcLD8Z2Z54q7s0vagjR5_sQ9nSiFb3GKyqMVGudVnWtmf9XVelCUCsmAH0PtbT-8_4Sl0xlkY5GjpwyFsCoGIe1L0I2hXH5_FMTJsxU7qpfkGi3p5PQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=2-%28MORFOLIN-4-IL%29-1%2C7-NAFTIRIDINAS&rft.inventor=KOPPITZ%2C+Marcus&rft.inventor=EBERSPACHER%2C+Uwe&rft.inventor=WORTMANN%2C+Lars&rft.inventor=SIEMEISTER%2C+Gerhard&rft.inventor=WEDLER%2C+Christine&rft.inventor=BADER%2C+Benjamin&rft.inventor=MOOSMAYER%2C+Dieter&rft.inventor=VON+NUSSBAUM%2C+Franz&rft.inventor=LUCKING%2C+Ulrich&rft.inventor=WENGNER%2C+Antje+Margret&rft.inventor=BONE%2C+Wilhelm&rft.inventor=LIENAU%2C+Philip&rft.inventor=SCHICK%2C+Hans&rft.inventor=LEFRANC%2C+Julien&rft.inventor=BRIEM%2C+Hans&rft.inventor=EIS%2C+Knut&rft.inventor=GRUDZINSKA-GOEBEL%2C+Joanna&rft.date=2017-06-15&rft.externalDBID=A1&rft.externalDocID=PE20170666A1 |